Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression.

Bardia A, et al. J Clin Oncol. 2024;42(15):1738-1744.

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

Hurvitz SA, et al. NPJ Breast Cancer. 2024;10(1):33.

Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer.

Rugo HS, et al. J Clin Oncol. 2022;40(29):3365-3376.

Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.

Soares LR, et al. ESMO open. 2023;8(4):101613.

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm.

Yang C, et al. Ther Adv Med Oncol. 2023;15: 17588359231175440.